Neoantigens in ovarian cancer: embarrassment of riches or needles in a haystack?

Por McNeish, Iain A.
Publicado no Clin Cancer Res (2018)

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting

Por Tookman, Laura, Krell, Jonathan, Nkolobe, Baleseng, Burley, Laura, McNeish, Iain A.
Publicado no Ther Adv Med Oncol (2020)

CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus

Por Elmetwali, Taha, Searle, Peter F, McNeish, Iain, Young, Lawrence S, Palmer, Daniel H
Publicado em 2010

Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer

Por Coley, Helen M., Hatzimichael, Eleftheria, Blagden, Sarah, McNeish, Iain, Thompson, Alastair, Crook, Tim, Syed, Nelofer
Publicado em 2012

Vaccinia Virus Induces Programmed Necrosis in Ovarian Cancer Cells

Por Whilding, Lynsey M, Archibald, Kyra M, Kulbe, Hagen, Balkwill, Frances R, Öberg, Daniel, McNeish, Iain A
Publicado em 2013

Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models

Por Li, Chang, Course, Meredith M., McNeish, Iain A., Drescher, Charles W., Valdmanis, Paul N., Lieber, André
Publicado no Cancer Res (2019)

Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management

Por Rumford, Megan, Lythgoe, Mark, McNeish, Iain, Gabra, Hani, Tookman, Laura, Rahman, Nazneen, George, Angela, Krell, Jonathan
Publicado no Sci Rep (2020)

Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors

Por Coughlan, Lynda, Alba, Raul, Parker, Alan L., Bradshaw, Angela C., McNeish, Iain A., Nicklin, Stuart A., Baker, Andrew H.
Publicado em 2010

“Re-educating” tumor-associated macrophages by targeting NF-κB

Por Hagemann, Thorsten, Lawrence, Toby, McNeish, Iain, Charles, Kellie A., Kulbe, Hagen, Thompson, Richard G., Robinson, Stephen C., Balkwill, Frances R.
Publicado em 2008

Pharmacological inhibition of β3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity

Por Browne, Ashley, Tookman, Laura A., Ingemarsdotter, Carin K., Bouwman, Russell D., Pirlo, Katrina, Wang, Yaohe, McNeish, Iain A., Lockley, Michelle
Publicado no Cancer Res (2015)

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer

Por McGivern, Niamh, El-Helali, Aya, Mullan, Paul, McNeish, Iain A., Paul Harkin, D., Kennedy, Richard D., McCabe, Nuala
Publicado no Oncotarget (2017)

In Vivo Retargeting of Adenovirus Type 5 to αvβ6 Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery

Por Coughlan, Lynda, Vallath, Sabari, Saha, Antonio, Flak, Magdalena, McNeish, Iain A., Vassaux, Georges, Marshall, John F., Hart, Ian R., Thomas, Gareth J.
Publicado em 2009

Inhibition of the Inflammatory Cytokine TNF-α Increases Adenovirus Activity in Ovarian Cancer via Modulation of cIAP1/2 Expression

Por Salako, Michael A, Kulbe, Hagen, Ingemarsdotter, Carin K, Pirlo, Katrina J, Williams, Sarah L, Lockley, Michelle, Balkwill, Frances R, McNeish, Iain A
Publicado em 2011

Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells

Por Connell, Claire M., Shibata, Atsushi, Tookman, Laura A., Archibald, Kyra M., Flak, Magdalena B., Pirlo, Katrina J., Lockley, Michelle, Wheatley, Sally P., McNeish, Iain A.
Publicado em 2011

RAD51 and BRCA2 enhance oncolytic adenovirus type 5 activity in ovarian cancer

Por Tookman, Laura A., Browne, Ashley K., Connell, Claire M., Bridge, Gemma, Ingemarsdotter, Carin K., Dowson, Suzanne, Shibata, Atsushi, Lockley, Michelle, Martin, Sarah A., McNeish, Iain A.
Publicado no Mol Cancer Res (2015)

p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker

Por Flak, Magdalena B, Connell, Claire M, Chelala, Claude, Archibald, Kyra, Salako, Michael A, Pirlo, Katrina J, Lockley, Michelle, Wheatley, Sally P, Balkwill, Frances R, McNeish, Iain A
Publicado em 2010

Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume

Por Rockall, Andrea G., Avril, Norbert, Lam, Raymond, Iannone, Robert, Mozley, P. David, Parkinson, Christine, Bergstrom, Donald, Sala, Evis, Sarker, Shah-Jalal, McNeish, Iain A., Brenton, James D.
Publicado no Clin Cancer Res (2014)

CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity

Por Walton, Josephine B., Farquharson, Malcolm, Mason, Susan, Port, Jennifer, Kruspig, Bjorn, Dowson, Suzanne, Stevenson, David, Murphy, Daniel, Matzuk, Martin, Kim, Jaeyeon, Coffelt, Seth, Blyth, Karen, McNeish, Iain A.
Publicado no Sci Rep (2017)

Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity

Por Walton, Josephine B., Farquharson, Malcolm, Mason, Susan, Port, Jennifer, Kruspig, Bjorn, Dowson, Suzanne, Stevenson, David, Murphy, Daniel, Matzuk, Martin, Kim, Jaeyeon, Coffelt, Seth, Blyth, Karen, McNeish, Iain A.
Publicado no Sci Rep (2018)

Failure of Translation of Human Adenovirus mRNA in Murine Cancer Cells Can be Partially Overcome by L4-100K Expression In Vitro and In Vivo

Por Young, Anna-Mary, Archibald, Kyra M, Tookman, Laura A, Pool, Alexander, Dudek, Kate, Jones, Carolyn, Williams, Sarah L, Pirlo, Katrina J, Willis, Anne E, Lockley, Michelle, McNeish, Iain A
Publicado em 2012